Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: geewiz who wrote (94)	12/21/1997 3:23:00 PM
From: Michael C. Woodward	Read Replies (1) \| Respond to of 534

Glad to see some activity on this thread. This company will perform well in 1998. The addition of Jim O'Shea as COB/President will do a lot for the stock. If you can access Edgar Online, you might want to review BJCT's Schedule 14A dated 12/18/97. This will give you a lot of insight on BJCT's relationship with Elan. If they get stockholder approval, look out. I am holding a ton of this stock and have more in an investment group that I am in. Expecting this stock to go to $5 by mid-1998.

To: geewiz who wrote (94)	12/21/1997 4:43:00 PM
From: Marc Kahn	Read Replies (2) \| Respond to of 534

In October, I saw a mock-up prototype of the Elan/Bioject glucose monitoring system. There are 2 pieces: a "patch" and a monitor that looks like a wrist watch. The "patch" is a plastic platform with an adhesive surface, which is designed to be stuck to the chest of the patient. A second piece is hinged on one end of the patch and comes down, snapping into place. This causes a tiny needle to be inserted into the skin. This needle is what is used to sample the interstitial fluids. A radio signal is sent to the wristwatch, storing history and displaying the current blood glucose level. The analysis of interstitial fluids is apparently a very accurate method to determine blood glucose. However, it is delayed about 10 minutes. This delay is considered to be a non-issue. Art, I looked at the information available about Integ. The main difference that I can see is that the Bioject JV product will produce continual monitoring, while Integ's product will only do "on demand" monitoring. The main advantages of the JV tools will be: - the ability to store history - the ability to know whether blood glucose is currently rising or falling. It would require very frequent "on demand" testing to see such a trend. When I described this to my brother, who is a physician, he immediately jumped on the possibility of using the continual monitoring as the input needed to drive an automatic insulin pump. He is excited about the potential to fine-tune blood sugar levels in this way. Happy Holidays to all, Marc Kahn